Page last updated: 2024-11-09

4-(4-dimethylaminostyryl)-1-methylpyridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(4-dimethylaminostyryl)-1-methylpyridinium: fluorescent probe for living cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-[4-(dimethylamino)styryl]-N-methylpyridinium : A pyridinium cation obtained by methylation at position 1 of 4-(4-dimethylaminostyryl)pyridine [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID730769
CHEMBL ID1617007
CHEBI ID72542
SCHEMBL ID1898080
MeSH IDM0100937

Synonyms (22)

Synonym
AKOS001579546
n,n-dimethyl-4-[(e)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]aniline
SCHEMBL1898080
4-{(e)-2-[4-(dimethylamino)phenyl]ethenyl}-1-methylpyridinium
4-[4-(dimethylamino)styryl]-n-methylpyridinium
4-[4-(dimethylamino)styryl]-1-methylpyridinium
48174-78-3
pyridinium, 4-[2-[4-(dimethylamino)phenyl]ethenyl]-1-methyl-
chebi:72542 ,
CHEMBL1617007
dndi1416976
AB00086619-01
4-(4-dimethylaminostyryl)-1-methylpyridinium
n,n-dimethyl-4-[(e)-2-(1-methyl-4-pyridin-1-iumyl)ethenyl]aniline;iodide
cid_5333955
dimethyl-[4-[(e)-2-(1-methylpyridin-1-ium-4-yl)vinyl]phenyl]amine;iodide
bdbm39691
Q27139972
AO-289/25117037
4-{2-[4-(dimethylamino)phenyl]vinyl}-1-methylpyridinium
4-[(1e)-2-[4-(dimethylamino)phenyl]ethenyl]-1-methylpyridin-1-ium
4-(4-(dimethylamino)styryl)-1-methylpyridin-1-ium

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The existence of a drug-drug interaction should be investigated when pazopanib is associated with a substrate of these transporters."( Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.
Chatelut, E; Delmas, C; Deluche, T; Hennebelle, I; Imbs, DC; Sauzay, C; Thomas, F; White-Koning, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinium ion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1864503Inhibition of human OCT3 mediated Famotidine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864509Substrate uptake in empty vector transfected (OCT3 null) HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864508Substrate uptake at human OCT3 overexpressed in HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864504Inhibition of human OCT3 mediated N-Ethyllidocaine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864502Inhibition of human OCT3 mediated (S,S)-Ethambutol uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864505Inhibition of human OCT3 mediated methylscopolamine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (15.00)18.7374
1990's4 (10.00)18.2507
2000's16 (40.00)29.6817
2010's11 (27.50)24.3611
2020's3 (7.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.98 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (97.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]